Morphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing Candidates for COVID-19

Carmen Mirabelli et al. 19 Nov 2020
Scienceonline
0 commento




Abstract


The global spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the associated disease COVID-19, requires therapeutic interventions that can be rapidly translated to clinical care. Unfortunately, traditional drug discovery methods have a >90% failure rate and can take 10-15 years from target identification to clinical use. In contrast, drug repurposing can significantly accelerate translation. We developed a quantitative high-throughput screen to identify efficacious single agents and combination therapies against SARS-CoV-2. Quantitative high-content morphological profiling was coupled with an AI-based machine learning strategy to classify features of cells for infection and stress. This assay detected multiple antiviral mechanisms of action (MOA), including inhibition of viral entry, propagation, and modulation of host cellular responses.

From a library of 1,425 FDA-approved compounds and clinical candidates, we identified 16 dose-responsive compounds with antiviral effects. In particular, we discovered that lactoferrin is an effective inhibitor of SARS-CoV-2 infection with an IC50 of 308 nM and that it potentiates the efficacy of both remdesivir and hydroxychloroquine. Lactoferrin also stimulates an antiviral host cell response and retains inhibitory activity in iPSC-derived alveolar epithelial cells, a model for the primary site of infection. Given its safety profile in humans, these data suggest that lactoferrin is a readily translatable therapeutic adjunct for COVID-19. Additionally, several commonly prescribed drugs were found to exacerbate viral infection and warrant clinical investigation. We conclude that morphological profiling for drug repurposing is an effective strategy for the selection and optimization of drugs and drug combinations as viable therapeutic options for COVID-19 pandemic and other emerging infectious diseases.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302203/

 

More about lactoferrin:

Lactoferrin as potential preventative and treatment for COVID-19

Lactoferrin as Protective Natural Barrier of Respiratory and Intestinal Mucosa against Coronavirus Infection and Inflammation

Una risposta contro il Covid-19: la glicoproteina lattoferrina, una componente dell’immunità innata

COVID-19 during Pregnancy and Postpartum: Antiviral Spectrum of Maternal Lactoferrin in Fetal and Neonatal Defense

Age and Location in Severity of COVID‐19 Pathology: Do Lactoferrin and Pneumococcal Vaccination Explain Low Infant Mortality and Regional Differences?

Vota questo articolo
(0 Voti)
Altro in questa categoria: « Age and Location in Severity of COVID‐19 Pathology: Do Lactoferrin and Pneumococcal Vaccination Explain Low Infant Mortality and Regional Differences? Therapeutic Effects of Lactoferrin in Ocular Diseases: From Dry Eye Disease to Infections »

Lascia un commento

Assicurati di aver digitato tutte le informazioni richieste, evidenziate da un asterisco (*). Non è consentito codice HTML.

Torna in alto

 

Scienzaonline con sottotitolo Sciencenew  - Periodico
Autorizzazioni del Tribunale di Roma – diffusioni:
telematica quotidiana 229/2006 del 08/06/2006
mensile per mezzo stampa 293/2003 del 07/07/2003
Scienceonline, Autorizzazione del Tribunale di Roma 228/2006 del 29/05/06
Pubblicato a Roma – Via A. De Viti de Marco, 50 – Direttore Responsabile Guido Donati

Photo Gallery